Drug Trial Radar · NCT05125016
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Nov 30, 2021
Primary completion
Mar 28, 2030
Study completion Mar 28, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (how the body reacts to the drug) and effectiveness (how well the drug works to shrink tumors) of REGN4336 when given in combination with REGN5678. The study has 2 parts. The purpose of Part 1 is to determine a safe dose(s) of REGN4336 to be given alone or in combination with REGN5678. Part 1 is known as the "dose escalation" phase. The purpose of Part 2, (known as the "dose expansion" phase), is to use the doses of REGN4336 and REGN5678 selected in Part 1 to further test how well the combination treatment with REGN4336 and REGN5678 works to shrink tumors. The study is looking at several other research questions, including: * What side effects may happen from taking REGN4336 alone or in combination with REGN5678 * How well does REGN4336 in combination with REGN5678 reduce tumor size * How much REGN4336 is in the blood at different times when it is given alone or in combination with REGN5678 * Does the body make antibodies against the study drugs (REGN4336 or REGN5678)
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
REGN4336Drug
Administered per the protocol
REGN5678Drug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: up to 21 days
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 5 years
- Incidence and severity of Serious Adverse Events (SAEs)Time frame: Up to 5 years
- Incidence and severity of Adverse Events of Special Interest (AESIs)Time frame: Up to 5 years
- REGN4336 monotherapy concentrations in serumTime frame: Up to 5 years
- REGN4336 concentrations in serum in combination with REGN5678Time frame: Up to 5 years
- Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)Time frame: Up to 5 years
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Stanford University Medical Center - Blake Wilbur Drive
Palo Alto, California · Recruiting
Yale University Hospital
New Haven, Connecticut · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Atrium Health Levine Cancer Institute
Charlotte, North Carolina · Recruiting
The Ohio State University James Cancer Hospital
Columbus, Ohio · Recruiting
Penn Medicine University of Pennsylvania Health System
Philadelphia, Pennsylvania · Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Withdrawn
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.